Urology News and Research

Latest Urology News and Research

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

CA-BSI can be reduced in children through quality improvement efforts: Study

Bloodstream infections associated with catheters can be significantly reduced through quality improvement efforts, possibly leading to better health outcomes and lives saved, decreased stays at the hospital and related costs, according to a new study.

4 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Investment report on Spectrum Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 May 2010

Researchers explore use of nanomedicine techniques for treatment of diseases in children

"Children are not small adults"—pediatricians say that's what makes their specialty different from the practice of medicine in adults. For similar reasons, researchers exploring the medical uses of nanotechnology believe that the use of molecular-level nanomedicine techniques in children will also require its own specialty.

3 May 2010

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with the filing of Watson's Abbreviated New Drug Application for choline fenofibrate delayed-release capsules in the 45 mg and 135 mg strengths.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

Pelvic Floor Institute launched to enhance physician knowledge on reconstruction procedures, techniques

Boston Scientific Corporation today announced the launch of the Pelvic Floor Institute -- a unique training forum and online resource designed to enhance physician knowledge and awareness of pelvic floor reconstruction procedures and techniques.

30 Apr 2010

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Calypso Medical Technologies, Inc., a developer of non-ionizing real-time localization technology used for the precise tracking of tumor targets, and Cancer Treatment Centers of America, a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment, announced today that with the installation of the Calypso System at the CTCA at Southwestern Regional Medical Center in Tulsa, Okla., Calypso's real-time tumor tracking technology is now available at all CTCA centers nationwide.

30 Apr 2010

Lucile Packard Children's Hospital opens new Center for Fetal Health

Complex fetal diagnoses bring extraordinary strain to pregnant women and their families. Learning an eagerly-awaited child will be born with a medical problem is often the worst crisis an expectant parents can face.

30 Apr 2010

A major research initiative to optimize quality of life for cancer survivors

At the age of 12, she was diagnosed with spinal cord cancer, with a nasty tumor sitting at the very base of her spinal cord and getting entangled with spinal nerves.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application for sirolimus tablets in the 1 mg and 2 mg strengths.

29 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Teleflex' first-quarter 2010 revenues down 1%

Teleflex Incorporated today announced financial results for the first quarter ended March 28, 2010.

27 Apr 2010

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Researchers from Case Western Reserve University School of Dental Medicine and University Hospitals Case Medical Center report initial results from a small sample that inflammation from gum disease and prostate problems just might be linked. They discuss their new evidence in the Journal of Periodontology, the official journal of the American Academy of Periodontology.

27 Apr 2010

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.

27 Apr 2010

Urology News and Research

Latest Urology News and Research

Theragenics reports highest quarterly consolidated revenue of $20.3 million

CA-BSI can be reduced in children through quality improvement efforts: Study

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Investment report on Spectrum Pharmaceuticals

Researchers explore use of nanomedicine techniques for treatment of diseases in children

Watson Pharmaceuticals sued in connection with filing ANDA for generic equivalent of Trilipix

Majority of patients who appear healthy may be at risk for cardiovascular disease

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Pelvic Floor Institute launched to enhance physician knowledge on reconstruction procedures, techniques

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Lucile Packard Children's Hospital opens new Center for Fetal Health

A major research initiative to optimize quality of life for cancer survivors

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

NeoGenomics first-quarter revenue up 22%

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Teleflex' first-quarter 2010 revenues down 1%

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Watson Laboratories sued by Teva Women's Health over generic Cenestin ANDA

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in